Our recent take on Titan (NASDAQ:TTNP) analyst consensus
 | By Raphi Shpitalnik | Macroaxis Story |
Titan Pharma is scheduled to announce its earnings today. While many traders are getting carried away by overanalyzing healthcare space, it is reasonable to recap Titan Pharma under the recent economic conditions. We will analyze why Titan Pharma investors may still consider a stake in the business given the recent economic outlook.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Rifka Kats
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Titan Pharma has an asset utilization ratio of 36.43 percent. This suggests that the company is making $0.36 for each dollar of assets. An increasing asset utilization means that Titan Pharma is more efficient with each dollar of assets it utilizes for everyday operations.
What is the right price you would pay to acquire a share of Titan Pharmaceuticals? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our stock advisor page.
What is happening with Titan Pharmaceuticals this year
Annual and quarterly reports issued by Titan Pharmaceuticals are formal financial statements that are published yearly and quarterly and sent to Titan stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as Titan Pharmaceuticals often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.
Titan Pharmaceuticals Gross Profit
Titan Pharmaceuticals Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Titan Pharmaceuticals previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Titan Pharmaceuticals Gross Profit growth over the last 10 years. Please check Titan Pharmaceuticals' gross profit and other fundamental indicators for more details.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Titan Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.